DelveInsight’s, “Vitiligo Pipeline Insight 2025” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Vitiligo pipeline landscape. It covers the Vitiligo Marketed and Pipeline Drugs profiles, including clinical and nonclinical stage products. It also covers the vitiligo therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Discover the latest drugs and treatment options in the Vitiligo Pipeline. Dive into DelveInsight’s comprehensive report today! @ Vitiligo Pipeline Outlook
Key Takeaways from the Vitiligo Pipeline Report
- In May 2025, Incyte Corporation announced a study is to to evaluate the safety and efficacy of ruxolitinib cream in pediatric participants with nonsegmental vitiligo.
- In April 2025, Merck Sharp & Dohme LLC conducted a study is to learn about the safety of MK-6194 and how well people tolerate it. Researchers also want to learn if people who take MK-6194 have more of a decrease in the amount of vitiligo on their face compared to people who take placebo.
- DelveInsight’s Vitiligo Pipeline report depicts a robust space with 20+ active players working to develop 20+ pipeline therapies for Vitiligo treatment.
- The leading Vitiligo Companies such as AbbVie, Pfizer, Incyte Corporation, Dren Bio, Amgen, and others.
- Promising Vitiligo Pipeline Therapies such as Ruxolitinib Cream, PF-06651600, AS012, MK-6194, SYHX1901, Upadacitinib, VYN201 Gel, and others.
Stay ahead with the most recent pipeline outlook for Vitiligo. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Vitiligo Treatment Drugs
Vitiligo Emerging Drugs Profile
- Povorcitinib: Incyte Corporation
Povorcitinib (INCB54707) is an oral, highly selective Janus kinase 1 (JAK1) inhibitor, with a 52-fold greater affinity for JAK1 over JAK2. Its mechanism of action involves inhibiting JAK1-mediated cytokine signaling, a key pathway in hidradenitis suppurativa (HS) inflammation. By targeting JAK1, povorcitinib reduces pro-inflammatory cytokines, alleviating symptoms and improving disease outcomes in HS. Currently, it is in Phase III clinical trials for HS and vitiligo.
- AMG-714: Amgen
AMG-714, a fully human immunoglobulin monoclonal antibody (IgG1κ), binds to and inhibits the function of IL-15 in all of its forms (Cis, Trans, and soluble IL-15 bound to IL-15RA), and blocks IL-15-induced T cell proliferation. Currently, the drug is in Phase II stage of its clinical trial for the treatment of Vitiligo.
- DR-01: Dren Bio
DR-01 is a first-in-class antibody therapeutic designed to selectively deplete terminally differentiated cytotoxic cells such as autoreactive CD8 T cells, which are known to play a pathogenic role in various hematological and autoimmune diseases. Currently, the drug is in Phase I stage of its clinical trial for the treatment of Vitiligo.
The Vitiligo Pipeline Report Provides Insights into
- The report provides detailed insights about companies that are developing therapies for the treatment of Vitiligo with aggregate therapies developed by each company for the same.
- It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Vitiligo Treatment.
- Vitiligo Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- Vitiligo Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Vitiligo market
Explore groundbreaking therapies and clinical trials in the Vitiligo Marketed and Pipeline Drugs. Access DelveInsight’s detailed report now! @ New Vitiligo Drugs
Vitiligo Companies
Vie, Pfizer, Incyte Corporation, Dren Bio, Amgen, and others.
Vitiligo Pipeline report provides the therapeutic assessment of the Vitiligo Marketed and Pipeline Drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Oral
- Parenteral
- Intravitreal
- Subretinal
- Topical.
Vitiligo Products have been categorized under various Molecule types such as
- Recombinant fusion proteins
- Small molecule
- Monoclonal antibody
- Peptide
- Polymer
- Gene therapy
Unveil the future of Vitiligo Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ Vitiligo Market Drivers and Barriers
Scope of the Vitiligo Pipeline Report
- Coverage- Global
- Vitiligo Companies- AbbVie, Pfizer, Incyte Corporation, Dren Bio, Amgen, and others.
- Vitiligo Pipeline Therapies- Ruxolitinib Cream, PF-06651600, AS012, MK-6194, SYHX1901, Upadacitinib, VYN201 Gel, and others.
- Vitiligo Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- Vitiligo Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Get the latest on Vitiligo Therapies and clinical trials. Download DelveInsight’s in-depth pipeline report today! @ Vitiligo Companies, Key Products and Unmet Needs
Table of Content
- Introduction
- Executive Summary
- Vitiligo: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Vitiligo – DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Povorcitinib: Incyte Corporation
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- AMG-714: Amgen
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- DR-01: Dren Bio
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Drug name: Company name
- Drug profiles in the detailed report…..
- Inactive Products
- Vitiligo Key Companies
- Vitiligo Key Products
- Vitiligo- Unmet Needs
- Vitiligo- Market Drivers and Barriers
- Vitiligo- Future Perspectives and Conclusion
- Vitiligo Analyst Views
- Vitiligo Key Companies
- Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/vitiligo-pipeline-insight